The Patent Finder

Vasopharm Biotech GmbH

Also on record
Records under this name other than patents Vasopharm Biotech GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Vasopharm Biotech GmbH

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,016,431Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,493,075Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,925,877Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 12,458,644Process for Preparing Solutions Comprising Biopterin Derivatives
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,895,372Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,717,522Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,222,238Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
Formerly held
Term ended
Term ended Apr 22, 2024 · USPTO record
Term endedTerm ended Apr 22, 2024USPTO record
US 7,541,3604-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
Formerly held
Term ended
Term ended Dec 30, 2023 · USPTO record
Term endedTerm ended Dec 30, 2023USPTO record
US 9,382,252Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
Formerly held
Term ended
Term ended Oct 8, 2023 · USPTO record
Term endedTerm ended Oct 8, 2023USPTO record
US 9,422,289Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
Formerly held
Term ended
Term ended Oct 8, 2023 · USPTO record
Term endedTerm ended Oct 8, 2023USPTO record
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited